/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Vir Biotechnology Inc Share Price Today: Live Updates & Key Insights

Vir Biotechnology Inc share price today is $9.48, up -3.46%. The stock opened at $9.725 against the previous close of $9.82, with an intraday high of $9.74 and low of $9.32.

Vir Biotechnology Inc Share Price Chart

style
pb-0

Vir Biotechnology Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Vir Biotechnology Inc Share Price Performance

$9.48 -0.0346(-3.46%) VIR at 13 Mar 2026 03:46 PM Biotechnology
Lowest Today 9.32
Highest Today 9.74
Today’s Open 9.725
Prev. Close 9.82
52 Week High 10.94
52 Week Low 4.16
Day’s Range: Low 9.32 High 9.74
52-Week Range: Low 4.16 High 10.94
1 day return -
1 Week return -0.99
1 month return +27.01
3 month return +40.89
6 month return +97.39
1 year return +35.35
3 year return -57.87
5 year return -81.82
10 year return -

Vir Biotechnology Inc Institutional Holdings

SB INVESTMENT ADVISERS (UK) LTD 10.44

BlackRock Inc 9.99

ARCH VENTURE CORP 8.08

Vanguard Group Inc 7.85

iShares Core S&P Small-Cap ETF 3.62

State Street Corp 3.28

Vanguard Total Stock Mkt Idx Inv 2.19

FMR Inc 1.98

Morgan Stanley - Brokerage Accounts 1.68

Dimensional Fund Advisors, Inc. 1.59

Vanguard Small Cap Index 1.58

Orbimed Advisors, LLC 1.49

Geode Capital Management, LLC 1.41

State Street® SPDR® S&P® Biotech ETF 1.39

iShares Russell 2000 ETF 1.35

FIAM Small Cap Core Composite 1.13

FIAM Small Cap Core CIT Cl B 1.11

The Goldman Sachs Group Inc 0.95

Vanguard Small Cap Growth Index Inv 0.88

Millennium Management LLC 0.87

Aberdeen Group PLC 0.87

Balyasny Asset Management LLC 0.86

Hudson Bay Capital Management LP 0.83

Vanguard Institutional Extnd Mkt Idx Tr 0.64

Biotech Growth Ord 0.59

GordonMD Global Investments LP 0.58

Northern Trust Corp 0.57

Charles Schwab Investment Management Inc 0.57

JPMorgan Chase & Co 0.56

Fidelity Small Cap Index 0.55

State Street SPDR Port S&P 600 Sm CpETF 0.55

Citadel Advisors Llc 0.50

iShares Russell 2000 Value ETF 0.48

Vanguard Strategic Equity Inv 0.46

Vanguard Tax-Managed Small Cap Adm 0.45

iShares Biotechnology ETF 0.44

DFA US Small Cap I 0.38

abrdn Healthcare Investors 0.37

Fidelity Series Small Cap Core 0.36

State St Russell Sm/Mid Cp® Indx SL Cl I 0.34

Vir Biotechnology Inc Market Status

Strong Buy: 2

Buy: 5

Hold: 2

Sell: 0

Strong Sell: 0

Vir Biotechnology Inc Fundamentals

Market Cap 1569.35 M

PB Ratio 2.0632

PE Ratio 0.0

Enterprise Value 1209.77 M

Total Assets 1002.82 M

Volume 3784269

Vir Biotechnology Inc Company Financials

Annual Revenue FY25:68556000 68.6M, FY23:51681000 51.7M, FY22:1580472000 1580.5M, FY21:1087068000 1087.1M, FY20:76368000 76.4M

Annual Profit FY25:56850000 56.9M, FY23:43718000 43.7M, FY22:1434153000 1434.2M, FY21:1021203000 1021.2M, FY20:76368000 76.4M

Annual Net worth FY25:-437987000 -438.0M, FY23:-600691000 -600.7M, FY22:515837000 515.8M, FY21:528584000 528.6M, FY20:-298665000 -298.7M

Quarterly Revenue Q4/2025:64070000 64.1M, Q3/2025:240000 0.2M, Q2/2025:1214000 1.2M, Q1/2025:3032000 3.0M, Q3/2024:2380000 2.4M

Quarterly Profit Q4/2025:430631000 430.6M, Q3/2025:-151212000 -151.2M, Q2/2025:-96306000 -96.3M, Q1/2025:-114583000 -114.6M, Q3/2024:2330000 2.3M

Quarterly Net worth Q4/2025:-42923000 -42.9M, Q3/2025:-163141000 -163.1M, Q2/2025:-110958000 -111.0M, Q1/2025:-120965000 -121.0M, Q3/2024:-213717000 -213.7M

About Vir Biotechnology Inc & investment objective

Company Information Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Organisation Biotechnology

Employees 367

Industry Biotechnology

CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow